Photo by nci from unsplash
e14600Background: Nivolumab (NIVO), a PD-1 inhibitor, is used in various advanced malignancies with meaningful and durable outcomes. However, its use can be limited by severe immune-related adverse... Click to show full abstract
e14600Background: Nivolumab (NIVO), a PD-1 inhibitor, is used in various advanced malignancies with meaningful and durable outcomes. However, its use can be limited by severe immune-related adverse...
Keywords:
analysis large;
patient cohort;
immune related;
large patient;
related adverse
Journal Title: Journal of Clinical Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!